Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 11
Submit an article Journal homepage
739
Views
87
CrossRef citations to date
0
Altmetric
Reviews

Development of Vi conjugate – a new generation of typhoid vaccine

Shousun Chen SzuEunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, 9402 Wildoak Drive, Bethesda, Maryland, MD 20814, USA+1 240 606 [email protected]
Pages 1273-1286 | Published online: 09 Jan 2014

References

  • Wright AE. On association of serious haemorrhages with conditions of defective blood-coagulability. Lancet 2, 807–809 (1896).
  • Marsden RW. inoculation with typhoid vaccine as a preventive of typhoid fever. Br. Med. J. 1(2052), 1017–1018 (1900).
  • Green, PH. Cases of typhoid fever in children. Prov. Med. Surg. J. 7(181), 468–470 (1844).
  • Crump JA. Luby SP, Mintz ED. The global burden of typhoid fever. Bull. Wld. Hlth. Org. 82, 346–353 (2004).
  • Ochai RL, Acosta CJ, Danovaro-Holiday MC et al. and the Domi Typhoid Study Group. 2008. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull. Wld. Hlth. Org. 86, 260–268 (2008).
  • Parry CM, Ho VA, Phuong LT et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob. Agents Chemother. 51, 819–825 (2007).
  • Zaki SA, Karande S. Multidrug-resistant typhoid fever: a review. J. Infect. Dev. Ctries. 5(5), 324–337 (2011).
  • Mermin JH, Villar R, Carpenter J et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J. Infect. Dis. 179, 1416–1422 (1999).
  • Mason WP. Typhoid mary. Science 30(760), 117–118 (1909).
  • Senthilkumar B, Prabakaran G. Multidrug resistant Salmonella typhi in asymptomatic typhoid carriers among food handlers in Namakkal district, Tamil Nadu. Indian J. Med. Microbiol. 23(2), 92–94 (2005).
  • Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am. J. Gastroenterol. 97, 784–787 (2000).
  • Engleberg NC, Barrett TJ, Fisher H, Porter B, Hurtado E, Hughes JW. Identification of a carrier by using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever on an Indian reservation. J. Clin. Microbiol. 18, 1320–1322 (1983).
  • Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev. Vaccines 9(5), 485–496 (2010).
  • McGregor AC, Waddington CS, Pollard AJ. Prospects for prevention of Salmonella infection in children through vaccination. Curr. Opin. Infect. Dis. 26, 254–262 (2013).
  • Wahdan MH, Serie C, Germanier R et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bull. World Health Organ. 58(3), 469–474 (1980).
  • Acharya IL, Lowe CU, Thapa R et al. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report one year after immunization. N. Engl. J. Med. 317, 1101–1104 (1987).
  • Klugman KP, Gilbertson IT, Koornhof HJ et al. and Vaccine Advisory Committee. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 2, 165–169 (1987).
  • Yang HH, Wu CG, Xie GL et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull. World Health Org. 79, 625–631 (2001).
  • Simanjuntak CH, Paleologo FP, Punjabi NH et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338(8774), 1055–1059 (1991).
  • Yang HH, Kilgore PE, Yang LH et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J. Infect. Dis. 183(12), 1775–1780 (1999).
  • Khan MI, Soofi SB, Ochiai RL et al. and DOMI Typhoid Karachi Vi Effectiveness Study Group. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 30(36), 5389–5395 (2012).
  • Mtove, G, Amos B, von Seidlein L et al. Invasive Salmonelloses among children admitted to a rural Tanzanian hospital and a comparison with previous studies. PLoS ONE 2, 1–8 (2010).
  • House D, Wain J, Ho VA et al. Serology of typhoid fever in an area of endemicity and its relevance to diagnosis. J. Clin. Microbiol. 39, 1002–1007 (2001).
  • The diagnosis, treatment and prevention of typhoid fever. World Health Org. Vaccine Biol. 03/07, 1–38 (2003).
  • Keddy KH, Sooka A, Letsoalo ME et al. Sensitivity and specificity of typhoid fever rapid antibody tests for laboratory diagnosis at two sub-Saharan African sites. Bull. World Health Org. 89, 640–647 (2011).
  • Brooks, WA, A. Hossain, D. Goswami et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg. Infect. Dis. 11, 326–329 (2005).
  • Sinha, A., S. Sazawal, R. Kumar et al. Typhoid fever in children ages less than 5 years. Lancet 354, 734–737 (1999).
  • Owais A, Sultana S, Zaman U, Rizvi A, Zaidi AK. Incidence of typhoid bacteremia in infants and young children in southern coastal Pakistan. Pediatr. Infect. Dis. J. 29(11), 1035–1039 (2010).
  • Saha SK, Baqui AH, Hanif M et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr. Infect. Dis. J. 20(5), 521–524 (2001).
  • Robbins, JD, Robbins JB. 1984. Re-examination of the immunopathogenic role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 150, 436–449 (1984).
  • Robbins JB, Schneerson R, Acharya IL et al. Protective roles of mucosal and serum immunity against typhoid fever. Monogr. Allergy 24, 315–320 (1988).
  • Zhang Q, Choo S, Everard J et al. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect. Immun. 68, 2692–2697 (2000).
  • Choo S, Zhang Q, Seymour L et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J. Infect. Dis. 182, 1260–1263 (2000).
  • Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 30(48), 6802–6808 (2012).
  • Armand J, Arminjon F, Mynard MC, Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J. Biol. Stand. 10(4), 335–339 (1982).
  • Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 28(24), 4073–4078 (2010).
  • Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: what more do we know? (Review). Curr. Opin. Infect. Dis. 25(3), 243–249 (2012).
  • Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12(3), 195–199 (1994).
  • Robbins JB, Schneerson R, Anderson P, Smith DH. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 276(14), 1181–1185 (1996).
  • Claesson BA, Trollfors B, Anderson PW et al. Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 15(2), 170–172 (1996).
  • Elemraid MA, Rushton SP, Shirley MD et al. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia. Epidemiol. Infect. 19, 1–8 (2012).
  • Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 y. Hum. Vaccine Immunother. 8(12): XXX (2012).
  • Robbins JB, Schneerson R, Szu SC, Fattom A, Yang Y, Lagergard T, Chu C, Sørensen US. Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates (Review). Curr. Top. Microbiol. Immunol. 146, 169–180 (1989).
  • Lanh MN, Bay PV, Ho TC et al. Persistent efficacy of Vi conjugates against typhoid fever in young children. N. Engl. J. Med. 349, 1390–1391 (2003).
  • Stone AL, Szu SC. Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever. J. Clin. Microbiol. 26(4), 719–725 (1988).
  • Szu SC, Li XR, Stone AL, Robbins JB. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59(12), 4555–4561 (1991).
  • Szu SC, Li XR, Schneerson R, Vickers JH, Bryla D, Robbins JB. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun. 57(12), 3823–3827 (1989).
  • Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166(5), 1510–1524 (1987).
  • Szu SC, Taylor DN, Trofa AC. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 62(10), 4440–4444 (1994).
  • Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65(6), 2088–2093 (1997).
  • An SJ, Yoon YK, Kothari S et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine 30, 1023–1028 (2012).
  • Lu YJ, Zhang F, Sayeed S et al. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. Vaccine 30(23), 3405–3412 (2012).
  • Micoli F, Rondini S, Pisoni I et al. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. Vaccine 30, 853–861 (2012).
  • Rijpkema S, Durrani Z, Lemercinier X, Jones C. Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay. Biologicals 32(1), 11–16 (2004).
  • Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY, Gotschlich EC. Standardization may suffice for licensure of conjugate vaccines. Dev. Biol. Stand. 95, 161–167 (1988).
  • Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccine Bull. Worlld Health Org. Tech. Rep. Ser. 962 ( Annex 2), 117–171 (2006).
  • Hendriksen CFM. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev. Vaccines 8(3), 313–322 (2008).
  • Kossaczka Z, Lin FY, Ho VA et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67(11), 5806–5810 (1999).
  • Lin, F. Y. C., Ho VA. Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344, 1263–1269 (2001).
  • Thiem VD, Lin FY, Canh DG et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin. Vaccine Immunol. 18(5), 730–735 (2011).
  • Canh DG, Lin FY, Thiem VD et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect. Immun.72(11), 6586–6588 (2004).
  • Lin FY, Vo AH, Phan VB et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 62(5), 644–648 (2000).
  • Fernández J, Balter S, Feris J et al. Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am. J. Trop. Med. Hyg. 62, 485–490 (2000).
  • Ahman H, Käyhty H, Vuorela A, Leroy O, Eskola J. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17(20), 2726–2732 (1999).
  • van Damme P, Kafeja F, Anemona A et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 6, e25398 (2011).
  • Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine 21, 3389–3392 (2003).
  • Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J. Infect. Dis. 190(2), 335–340 (2004).
  • Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14(5), 435–438 (1996).
  • Fattom A, Lue C, Szu, SC et al. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect. Immun. 58, 2309–2312 (1990).
  • Konadu EY, Parke JC Jr, Tran HT, Bryla DA, Robbins JB, Szu SC. Investigational vaccine for Escherichia coli O157: Phase 1 study of O157 O-specific polysaccharide Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugates in adults. J. Infect. Dis. 177, 383–387 (1998).
  • Passwell JH, Ashkenazi S, Harlev E et al., and Israel Shigella Study Group. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr. Infect. Dis. J. 22, 701–706 (2003).
  • Fattom A, Fuller S, Propst M et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23, 656–663 (2004).
  • Coalition against typhoid. The 8th International Conference on Typhoid Fever and Other Invasive Salmonelloses. Bangladesh, 26 August 2013.
  • Rondini S, Micoli F, Lanzilao L et al. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi. J. Infect. Dev. Ctries. 6, 763–773 (2012).
  • Global routine vaccination coverage, 2010. Centers for Disease Control and Prevention (CDC). Morb. Mortal. Wkly. Rep. 60, 1520–1521 (2011).
  • Staats HF, Kirwan SM, Whisnant CC, Stephenson JL, Wagener DK, Majumder PP. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide. Clin. Vacc. Immunol. 17, 412–419 (2010).
  • Wahid R, Pasetti MF, Maciel M Jr et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin. Immunol. 138, 187–200 (2011).
  • Sur D, Ochiai RL, Bhattacharya SK et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N. Engl. J. Med. 361, 335–344 (2009).
  • Broome CV. Vaccine efficacy determination. NIPH Ann. 14, 219–221; discussion 222–224 (1991).
  • Robbins JB, Whisnant JK, Schneerson R, Parke JC Jr. Quantitative measurement of the “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7, 103–110 (1973).
  • Quataert SA, Kirch CS, Wield LJQ et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum, Lot 89-S. Clin. Diag. Lab. Immun. 2, 590–597 (1995).
  • Holder PK, Maslanka SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin. Diag. Lab. Immun. 2, 132–137 (1995).
  • Szu SC, Hunt S, Xie GL et al. A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned. Vaccine 31(15),1970–1974 (2013).
  • Laboratory of Microbiology, In-Vivo Testing and Standards, Division of Biological Standards and Quality Control, Office of Compliance and Biologics Quality, Center for Biologics Evaluation & Research (CBER), US Food & Drug Administration.
  • Ellis H. Sir Almroth Wright: pioneer immunologist. Br. J. Hosp. Med. (Lond.) 72, 169 (2011).
  • Nelson CB and de Quadros C. Coalition against Typhoid (CaT): a new, global initiative to advance typhoid vaccination. Vaccine 29, 6443 (2011).
  • Pulickal AS, Pollard AJ. Vi polysaccharide–protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype? Expert Rev. Vaccines 6, 293–295 (2007).
  • Pier GB. Is Pseudomonas aeruginosa exotoxin A a good carrier for conjugate vaccine? Hum. Vaccines 3, 39–40 (2007).
  • Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum (Review). J. Infect. Dis. 171(6), 1387–1398 (1995).
  • Robbins JB, Schneerson R, Szu SC. Hypothesis: how licensed vaccines confer protective immunity (Review). Adv. Exp. Med. Biol. 397, 169–182 (1996).
  • Jones C, Lee CK, Ahn C et al. Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5–7 September 2012. Vaccine 31(41), 4466–4469 (2013).
  • Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine 27(10), 1609–1621 (2009).
  • Feasey NA, Dougan G, Kingsley RA, Heydeman RS, Gorden MA. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet 379, 2489–2499 (2012).
  • Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50, 241–246 (2010).
  • Konadu EY, Lin FY, Hó VA et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 68(3), 1529–1534 (2000).
  • Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella Typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60, 4679–4686 (1992).
  • Simon R, Tennant SM, Wang JY et al. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. Enteritidis. Infect. Immun. 79, 4240–4249 (2011).
  • Micoli F, Rondini S, Gavini M et al. A scalable method for O-antigen purification applied to various Salmonella serovars. Anal. Biochem. 434, 136–145 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.